Price movement over the last 24 hours
Albemarle Corp. vs American Well Corp — how do they compare? Albemarle Corp. trades at $127.96 (market cap $15.22B), while American Well Corp trades at $8.79 (market cap $150.21M). The key difference: Albemarle Corp. is far larger — about 101.3× American Well Corp's market cap, and Albemarle Corp. pays a 1.26% dividend while American Well Corp pays none. Which is the better fit depends on your goals.
| ALB | AMWL | |
|---|---|---|
Market Cap | $15.22B | $150.21M |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $9.83 |
52-Week Low | $67.30 | $3.78 |
Enterprise Value | $18.24B | -$25.04M |
Dividend Yield | 1.26% | — |
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
AMWL trades at $8.99, down 2.81% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving financial trends with revenue stabilizing near $249 million in 2025 and net losses narrowing to -$96 million. Recent news highlights momentum, including a Zacks upgrade to Buy on June 24, 2026, and Amazon appointing Amwell's co-founder to lead its healthcare unit on May 27, 2026.
Outlook remains cautious due to persistent losses and negative cash flow, though valuation metrics like P/S of 0.64 and P/B of 0.68 suggest potential upside if profitability improves. Risks include competitive pressures and execution challenges, but analyst consensus leans Hold with a $7.25 price target, indicating limited near-term growth expectations.
Trailing returns across standard periods
Latest headlines on both assets
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →